1.Maksymowych WP, Lambert RG, Brown LS, Pangan AL. Defining the Minimally Important Change for the SpondyloArthritis Research Consortium of Canada Spine and Sacroiliac Joint Magnetic Resonance Imaging Indices for Ankylosing Spondylitis. J Rheumatol. 2012;39(8):1666–74.
2.Xu X, Shen B, Zhang A, Liu J, Da Z, Liu H, et al. Anxiety and depression correlate with disease and quality-of-life parameters in Chinese patients with ankylosing spondylitis. Patient Prefer Adherence. 2016;10:879–85.
3.Shen B, Zhang A, Liu J, Da Z, Xu X, Liu H, et al. Body image disturbance and quality of life in Chinese patients with ankylosing spondylitis. Psychology and psychotherapy. 2014;87(3):324–37.
4.Chiowchanwisawakit P, Thaweeratthakul P, Wattanamongkolsil L, Srinonprasert V, Koolvisoot A, Muangchan C, et al. Relationship Between Health-Related Quality of Life and Patient Acceptable Symptom State With Disease Activity and Functional Status in Patients With Ankylosing Spondylitis in Thailand: A Cross-sectional Study. J Clin Rheumatol. 2018.
5.Park EK, Pak K, Park JH, Kim K, Kim SJ, Kim IJ, et al. Baseline increased 18F-fluoride uptake lesions at vertebral corners on positron emission tomography predict new syndesmophyte development in ankylosing spondylitis: a 2-year longitudinal study. Rheumatology international. 2017;37(5):765–73.
6.Kang KY, Kwok SK, Ju JH, Park KS, Park SH, Hong YS. The predictors of development of new syndesmophytes in female patients with ankylosing spondylitis. Scand J Rheumatol. 2015;44(2):125–8.
7.Arends S, Spoorenberg A, Efde M, Bos R, Leijsma MK, Bootsma H, et al. Higher bone turnover is related to spinal radiographic damage and low bone mineral density in ankylosing spondylitis patients with active disease: a cross-sectional analysis. PLoS One. 2014;9(6):e99685.
8.van Tubergen A, Ramiro S, van der Heijde D, Dougados M, Mielants H, Landewe R. Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis. 2012;71(4):518–23.
9.Bagchi S, Genardi S, Wang CR. Linking CD1-Restricted T Cells With Autoimmunity and Dyslipidemia: Lipid Levels Matter. Front Immunol. 2018;9:1616.
10.Sakellariou GT, Iliopoulos A, Konsta M, Kenanidis E, Potoupnis M, Tsiridis E, et al. Serum levels of Dkk–1, sclerostin and VEGF in patients with ankylosing spondylitis and their association with smoking, and clinical, inflammatory and radiographic parameters. Joint Bone Spine. 2017;84(3):309–15.
11.Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, et al. High level of functional dickkopf–1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(4):572–4.
12.Danese E, Montagnana M, Lippi G. Proteomics and frailty: a clinical overview. Expert Rev Proteomics. 2018.
13.Guo L, Ren L, Zhang C. Relationship between depression and inflammatory factors and brain-derived neurotrophic factor in patients with perimenopause syndrome. Exp Ther Med. 2018;15(5):4436–40.
14.Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286–91.
15.Zhu TY, Tam LS, Lee VW, Hwang WW, Li TK, Lee KK, et al. Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. Rheumatology (Oxford). 2008;47(9):1422–5.
16.Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994;21(9):1694–8.
17.Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1:20.
18.Zung WW. A rating instrument for anxiety disorders. Psychosomatics. 1971;12(6):371–9.
19.Zung WW. A Self-Rating Depression Scale. Arch Gen Psychiatry. 1965;12:63–70.
20.de Klerk E, van der Heijde D, van der Tempel H, van der Linden S. Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. J Rheumatol. 1999;26(12):2635–41.
21.Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis. 2007;66(7):910–5.
22.Braun J, Golder W, Bollow M, Sieper J, van der Heijde D. Imaging and scoring in ankylosing spondylitis. Clin Exp Rheumatol. 2002;20(6 Suppl 28):S178–84.
23.Heuft-Dorenbosch L, Landewe R, Weijers R, Wanders A, Houben H, van der Linden S, et al. Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back pain. Ann Rheum Dis. 2006;65(6):804–8.
24.Creemers MC, Franssen MJ, van’t Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64(1):127–9.
25.Tan S, Dasgupta A, Yao J, Flynn JA, Yao L, Ward MM. Spatial distribution of syndesmophytes along the vertebral rim in ankylosing spondylitis: preferential involvement of the posterolateral rim. Ann Rheum Dis. 2016;75(11):1951–7.
26.Machado P, Landewe R, Braun J, Hermann KG, Baker D, van der Heijde D. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis. 2010;69(8):1465–70.
27.Tan S, Wang R, Ward MM. Syndesmophyte growth in ankylosing spondylitis. Curr Opin Rheumatol. 2015;27(4):326–32.
28.van Tubergen A, van der Heijde D, Dougados M, Mielants H, Landewe R. Are syndesmophytes most prevalent in the lumbar or in the cervical spine in patients with ankylosing spondylitis and do they develop in a specific direction? Rheumatology (Oxford). 2012;51(8):1432–9.
29.Braun J, Baraliakos X, Hermann KG, Xu S, Hsu B. Serum C-reactive Protein Levels Demonstrate Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab. J Rheumatol. 2016;43(9):1704–12.
30.Zhang JR, Liu XJ, Xu WD, Dai SM. Effects of tumor necrosis factor-alpha inhibitors on new bone formation in ankylosing spondylitis. Joint Bone Spine. 2016;83(3):257–64.
31.Kang KY, Ju JH, Park SH, Kim HY. The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis. Rheumatology. 2013;52(4):718–26.
32.Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Annals of the rheumatic diseases. 2018;77(1):63–9.
33.Braun J, Baraliakos X, Hermann KG, Deodhar A, van der Heijde D, Inman R, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Annals of the rheumatic diseases. 2014;73(6):1107–13.
34.O’Neill TW, McCloskey EV, Kanis JA, Bhalla AK, Reeve J, Reid DM, et al. The distribution, determinants, and clinical correlates of vertebral osteophytosis: a population based survey. J Rheumatol. 1999;26(4):842–8.
35.Aydin SZ, Can M, Alibaz-Oner F, Keser G, Kurum E, Inal V, et al. A relationship between spinal new bone formation in ankylosing spondylitis and the sonographically determined Achilles tendon enthesophytes. Rheumatol Int. 2016;36(3):397–404.
36.Ramiro S, Stolwijk C, van Tubergen A, van der Heijde D, Dougados M, van den Bosch F, et al. Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Ann Rheum Dis. 2015;74(1):52–9.
37.Maas F, Arends S, Wink FR, Bos R, Bootsma H, Brouwer E, et al. Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-alpha inhibitors. PLoS One. 2017;12(6):e0177231.
38.Al-Zaghal A, Yellanki DP, Ayubcha C, Werner TJ, Hoilund-Carlsen PF, Alavi A. CT-based tissue segmentation to assess knee joint inflammation and reactive bone formation assessed by (18)F-FDG and (18)F-NaF PET/CT: Effects of age and BMI. Hell J Nucl Med. 2018.
39.Kim SK, Choe JY, Lee SS, Shin K. Body mass index is related with the presence of syndesmophyte in axial spondyloarthritis: Data from the Korean College of Rheumatology BIOlogics (KOBIO) registry. Mod Rheumatol. 2017;27(5):855–61.
40.Levitskii LM, Makarychev AI, Roshchina LF. The dynamics of cortical activity in patients with obesity in relation to the degree and form of the disease. Vopr Pitan. 1960;19:16–21.
41.Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A, et al. Body weight, gender and response to TNF-alpha blockers in axial spondyloarthritis. Rheumatology (Oxford). 2014;53(5):875–81.
42.Huang JC, Qian BP, Qiu Y, Wang B, Yu Y, Zhu ZZ, et al. Quality of life and correlation with clinical and radiographic variables in patients with ankylosing spondylitis: a retrospective case series study. BMC musculoskeletal disorders. 2017;18(1):352.
43.Vesovic-Potic V, Mustur D, Stanisavljevic D, Ille T, Ille M. Relationship between spinal mobility measures and quality of life in patients with ankylosing spondylitis. Rheumatology international. 2009;29(8):879–84.
44.Ariza-Ariza R, Hernandez-Cruz B, Navarro-Sarabia F. Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Arthritis and rheumatism. 2003;49(4):483–7.
45.Ozdemir O. Quality of life in patients with ankylosing spondylitis: relationships with spinal mobility, disease activity and functional status. Rheumatology international. 2011;31(5):605–10.